Pfizer (PFE)
25.35
-0.30 (-1.17%)
NYSE · Last Trade: Jul 14th, 5:32 PM EDT
Detailed Quote
Previous Close | 25.65 |
---|---|
Open | 25.58 |
Bid | 25.35 |
Ask | 25.37 |
Day's Range | 25.34 - 25.63 |
52 Week Range | 20.92 - 31.54 |
Volume | 25,888,710 |
Market Cap | 142.13B |
PE Ratio (TTM) | 18.37 |
EPS (TTM) | 1.4 |
Dividend & Yield | 1.720 (6.79%) |
1 Month Average Volume | 39,599,520 |
Chart
About Pfizer (PFE)
Pfizer is a global biopharmaceutical company that develops and manufactures innovative medicines and vaccines to improve health outcomes for people around the world. Renowned for its extensive research and development efforts, Pfizer focuses on various therapeutic areas including vaccines, oncology, immunology, cardiology, endocrinology, and rare diseases. The company is committed to addressing significant health challenges through the discovery of new treatments, leveraging cutting-edge science and technology. Pfizer also emphasizes partnerships and collaborations to expand its capabilities and enhance access to healthcare solutions. Read More
News & Press Releases
Pfizer faces a $1 billion sales hit in 2025 from IRA reforms, flat EPS and revenue forecasts, and long-term risks tied to patent expirations.
Via Benzinga · July 14, 2025
BofA cuts Bristol Myers' 2025 EPS and sales estimates slightly and flags medium-term pressure from generics, while maintaining a Neutral rating.
Via Benzinga · July 14, 2025
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability.
But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
Via StockStory · July 14, 2025
Delaware's top court reversed a ruling that allowed expert testimony in Zantac cancer lawsuits, citing improper legal standards by the trial judge.
Via Benzinga · July 11, 2025
Donald Trump's proposed 200% tariffs can squeeze the profit margins of pharma companies, but LLY is poised to "benefit" except for the rest.
Via Benzinga · July 11, 2025
Fluarix and Flulaval are being shipped in single-dose, 0.5 mL pre-filled syringes and are not recommended for individuals with severe allergies to vaccine components or a history of Guillain-Barré syndrome.
Via Stocktwits · July 10, 2025
Xtandi plus leuprolide improved overall survival in prostate cancer patients in the Phase 3 EMBARK trial, with no new safety concerns reported.
Via Benzinga · July 10, 2025
A growing chorus of lawmakers, ethics watchdogs, and concerned citizens are reigniting a high-stakes debate: Should U.S. politicians be allowed to buy and sell stocks while in office?
Amidst rising public distrust and a series of high-profile investigations into lawmakers' financial dealings, calls to ban or heavily restrict stock
Via MarketMinute · July 10, 2025
Via Benzinga · July 10, 2025
Moderna's Spikevax receives FDA approval for use in high-risk children; Pfizer, BioNTech appeal U.K. ruling in COVID-19 vaccine patent dispute.
Via Benzinga · July 10, 2025
Via The Motley Fool · July 10, 2025
Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced positive topline results from the overall survival (OS) analysis from the Phase 3 EMBARK study evaluating XTANDI® (enzalutamide), in combination with leuprolide and as a monotherapy, in men with non-metastatic hormone-sensitive prostate cancer (nmHSPC; also known as nonmetastatic castration-sensitive prostate cancer or nmCSPC) with biochemical recurrence (BCR) at high risk for metastasis.
By Pfizer Inc. · Via Business Wire · July 10, 2025
The supercharged income stock coveted most by everyday investors is sporting a 5.14% yield.
Via The Motley Fool · July 10, 2025
Warren Buffett is indirectly invested in high-dividend yield stocks via Berkshire Hathaway Inc.'s subsidiary New England Asset Management.
Via Benzinga · July 9, 2025
Let's have a look at what is happening on the US markets on Tuesday. Below you can find the most active S&P500 stocks in today's session.
Via Chartmill · July 8, 2025
Via The Motley Fool · July 8, 2025
While Eli Lilly has struggled in the past year due to competitive pressures, the statistical winds may finally favor LLY stock.
Via Benzinga · July 7, 2025
Seemingly undervalued dividend stocks, such as BAC, F, MO, VZ, and PFE, offer a rare combination of strong yields and attractive valuations.
Via MarketBeat · July 7, 2025
Via The Motley Fool · July 7, 2025
Trump's $3.3 trillion domestic agenda bill, passed by the House on Thursday, includes a significant victory for pharmaceutical companies .
Via Benzinga · July 4, 2025
The parabolic ascent of artificial intelligence (AI) superstar Palantir Technologies may be short-lived.
Via The Motley Fool · July 4, 2025
By avoiding big swings, low-volatility stocks let investors focus on long-term fundamentals.
These stocks may not be up 100% in a single year, but they offer a measured approach to building wealth over time.
Via StockStory · July 4, 2025